+13.1%
GSK vs DUOL
-38.2%
+51.3%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | DUOL | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | +26.0% | -21.0% | +4.6% |
| 7D | +4.9% | +19.3% | -14.3% | +4.5% |
| 30D | +9.9% | +9.6% | +0.2% | +9.2% |
| 3M | +0.2% | +17.1% | -16.9% | -0.1% |
| 6M | +2.3% | +46.3% | -44.0% | +3.9% |
| YTD | +7.1% | -8.1% | +15.2% | +7.3% |
| 1Y | +13.1% | -38.5% | +51.6% | +13.1% |
| All | +13.1% | -38.2% | +51.3% | +13.1% |
Cumulative growth
Daily Returns
Daily percentage return beside DUOL.
Daily Out/Under-Performance
Portfolio return minus DUOL return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × DUOL return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded DUOL wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling